Prometheus Stock
| Valuation | $41B |
| Valuation Date | Jun 11, 2026 |
| Implied Valuation | $49.46B |
| Last Price | $51.87 |
| 52-Week High | $51.87 |
| 52-Week Low | $19.00 |
| YTD Return | n/a |
| 1-Year Return | n/a |
| 3-Year Return | n/a |
| Total Funding | $18.8B1 |
| Latest Round Amount | $12B1 |
| Latest Round | Series B |
| Funding Rounds | 2 |
| IPO Status | n/a |
| Expected IPO Date | n/a |
| Revenue | n/a |
| Revenue Type | n/a |
| P/S Ratio | n/a |
About Prometheus
Prometheus (formerly Project Prometheus) is an artificial intelligence company focused on the development of AI tools that help engineers design and manufacture physical products. The company's "AI engineer" will assist in the creation of computers, spacecraft, jet engines, and other advanced machines.
Invest in Prometheus
Want to invest in Prometheus? Try our partner below.
Hiive is a marketplace for buying and selling shares of private, pre-IPO companies. Invest in the world's most exciting startups before they go public.
Invest on HiiveStock Analysis may be compensated for user sign-ups through Hiive links. Hiive is not affiliated with Stock Analysis. Securities offered by Hiive Markets Limited, member of FINRA/SIPC.
Related Companies
News
Powerlaw Corp. (Nasdaq: PWRL) Announces Prometheus and Shield AI as Newest Holdings & Files Updated Schedule of Investments
SAN FRANCISCO--(BUSINESS WIRE)--Powerlaw Corp. (Nasdaq: PWRL), a publicly traded closed-end fund advised by Powerlaw Fund Adviser, LLC, today highlighted its newest portfolio holdings, Prometheus and ...
TSG Invest Adds Project Prometheus to Venture 50 as Cerebras Goes Public
HAUPPAUGE, N.Y., June 09, 2026 (GLOBE NEWSWIRE) -- TSG Invest, a multi-entity financial services firm providing accredited investors with research and access to pre-IPO opportunities, today announced ...
Meta signs nuclear energy deals to power Prometheus AI supercluster
Meta said it has secured agreements with energy companies Vistra, TerraPower and Oklo, which are working on nuclear power technologies. They're planning to work together to eventually power Meta's Pro...
Meta announces massive 'Prometheus' & 'Hyperion' data center plans
CNBC's Deirdre Bosa joins 'Money Movers' to discuss Big Tech's AI talent raid.
Merck beats on revenue boosted by Keytruda sales, but posts quarterly loss due to Prometheus deal
Shares of Merck are down roughly 4% this year, with a market value of roughly $270 billion, making it the third largest pharmaceutical company based in the U.S.
Wells Fargo's Mohit Bansal on Merck's $10.8B deal to buy Prometheus
Mohit Bansal, Wells Fargo securities analyst, joins 'Closing Bell: Overtime' to discuss Merck's acquisition of Prometheus and Moderna's positive cancer therapy trial results.
Merck's $10.8 Billion Prometheus Deal Has Citi Analysts Bullish
Prometheus' PRA023 drug can add 15% to 30% to Merck's long-term earnings once approved, according to Citi analysts.